Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Roche Holdings Ltd ADR (RHHBY)

Roche Holdings Ltd ADR (RHHBY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 294,099,808
  • Shares Outstanding, K 6,830,000
  • Annual Sales, $ 72,046 M
  • Annual Income, $ 15,241 M
  • 60-Month Beta 0.46
  • Price/Sales 4.31
  • Price/Cash Flow 12.59
  • Price/Book 9.54
Trade RHHBY with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 02/03/22
  • Annual Dividend & Yield 0.78 (1.79%)
  • Most Recent Dividend 0.776 on 03/17/22
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/22
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
39.3200 +9.51%
on 05/13/22
47.1600 -8.69%
on 04/29/22
-3.9400 (-8.38%)
since 04/27/22
3-Month
39.3200 +9.51%
on 05/13/22
53.8600 -20.05%
on 04/11/22
-4.5700 (-9.59%)
since 02/25/22
52-Week
39.3200 +9.51%
on 05/13/22
53.8600 -20.05%
on 04/11/22
-0.4300 (-0.99%)
since 05/27/21

Most Recent Stories

More News
Pharma Stock Roundup: EU Nod for AZN, JNJ & Others, PFE COVID Jab Effective in Kids

European Commission authorizes a booster dose of AstraZeneca's (AZN) COVID-19 vaccine and approves Merck (MRK) and Roche's (RHHBY) oncology drugs for expanded use.

AZN : 67.40 (+1.05%)
RHHBY : 43.0600 (-0.62%)
JNJ : 181.09 (+0.91%)
PFE : 53.91 (-0.15%)
MRK : 93.08 (+0.83%)
New Pivotal Data Demonstrate Clinical Benefit of Genentech’s Glofitamab, a Potential First-in-Class Bispecific Antibody for People With Aggressive Lymphoma

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that new pivotal data on its investigational CD20xCD3 T-cell engaging bispecific antibody, glofitamab, will be presented...

RHHBY : 43.0600 (-0.62%)
Roche (RHHBY) Gets EC Approval for Polivy Combination in DLBCL

Roche's (RHHBY) Polivy combination receives the European Commission's approval for patients with previously untreated diffuse large B-cell lymphoma.

RHHBY : 43.0600 (-0.62%)
GERN : 1.4000 (+8.53%)
ALKS : 30.54 (+4.02%)
SGEN : 141.39 (+2.12%)
Global Blood (GBT) Thrives on Oxbryta, Overdependence a Woe

Global Blood's (GBT) Oxbryta is approved for treating sickle cell disease. The recent label expansion nod to Oxbryta is a positive. However, sole dependence on Oxbryta for growth is a concern.

RHHBY : 43.0600 (-0.62%)
GBT : 26.15 (+2.71%)
AGLE : 1.5700 (+1.29%)
LPTX : 1.1100 (-7.50%)
Amgen (AMGN) Ahead of Industry This Year So Far: What's Next?

Amgen's (AMGN) key drugs like Prolia, Repatha, Xgeva and biosimilars are driving sales. Amgen is also rapidly advancing its robust pipeline of early and late-stage assets.

RHHBY : 43.0600 (-0.62%)
BMY : 76.14 (-1.87%)
AMGN : 255.26 (+0.87%)
ABBV : 150.00 (-0.38%)
Seagen (SGEN) Posts Positive Data from New Study on Tukysa

Seagen (SGEN) reports favorable data on the pivotal phase II MOUNTAINEER study evaluating Tukysa in combination with Herceptin for treating HER2-positive metastatic colorectal cancer.

RHHBY : 43.0600 (-0.62%)
MRK : 93.08 (+0.83%)
SGEN : 141.39 (+2.12%)
LPTX : 1.1100 (-7.50%)
ImmunoGen (IMGN) Ovarian Cancer Drug BLA Gets Priority Review

ImmunoGen (IMGN) gets priority review from the FDA for the BLA seeking approval for its lead candidate, mirvetuximab soravtansine, for treating platinum-resistant ovarian cancer.

RHHBY : 43.0600 (-0.62%)
LLY : 323.48 (+3.20%)
JAZZ : 150.91 (-1.02%)
IMGN : 3.84 (+4.35%)
Data at the 2022 ASCO Annual Meeting Highlight Genentech’s Continued Commitment to Innovation in Oncology and Personalized Healthcare

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that new data from clinical trials of 18 approved and investigational medicines across more than 20 cancer types will...

RHHBY : 43.0600 (-0.62%)
5 Reasons Why You Should Add Halozyme (HALO) to Your Portfolio

We provide five reasons, which make Halozyme (HALO) a good investment option in 2022.

RHHBY : 43.0600 (-0.62%)
JNJ : 181.09 (+0.91%)
HALO : 48.30 (+3.65%)
ARGX : 323.10 (+2.26%)
2 Mega-Cap Stocks to Buy on the Dip

Mega-cap stocks Walmart (WMT) and Roche Holding (RHHBY) are both down more than 15% in the past month but could be solid buy the dip candidates. The Fed has already announced two rate hikes within...

RHHBY : 43.0600 (-0.62%)
WMT : 128.48 (+1.97%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Key Turning Points

3rd Resistance Point 43.5833
2nd Resistance Point 43.4067
1st Resistance Point 43.2333
Last Price 43.0600
1st Support Level 42.8833
2nd Support Level 42.7067
3rd Support Level 42.5333

See More

52-Week High 53.8600
Fibonacci 61.8% 48.3057
Fibonacci 50% 46.5900
Fibonacci 38.2% 44.8743
Last Price 43.0600
52-Week Low 39.3200

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar